Lupin Gets TGA Nod, Faces US FDA Alerts

  Published 1 year ago

Lupin’s Dabhasa plant gets TGA GMP certification; Pithampur units receive FDA Form-483s with observations after inspections.

  • Dabhasa API facility certified by Australia’s TGA, enhancing Lupin’s global pharmaceutical manufacturing credibility.
  • Pithampur Unit-3 inspection ended with three observations; Unit-2 faced four, as per U.S. FDA Form-483s.
  • Lupin is committed to addressing issues, maintaining CGMP standards across facilities while expanding global contract manufacturing services.

You might like these

NextEra Launches: Saudi Arabia's Digital Future

PLI Pharma Scheme Exceeds Investment

India Bond Yields Steady, Rate Cut Expected

Maruti Suzuki Expands Solar Capacity to 30MWp, Eyes 319MWp by 2031

Mahindra & Mahindra Reports June 2025 Sales Growth

Lupin Launches Generic Oxcarbazepine ER Tablets in the U.S.

NYT Licenses Content to Amazon for AI Use

News that matters the most ⚡